Dr. Chiesa Fuxench discusses the role of topical ruxolitinib for patients with mild-to-moderate atopic dermatitis, including those who have not responded adequately to topical corticosteroids or who need a nonsteroidal option for sensitive areas. She reviews factors that influence patient selection, such as disease severity, body surface area involvement, treatment history, and when more extensive disease might warrant phototherapy or systemic therapy. Dr. Chiesa Fuxench also explains how topical ruxolitinib can be used intermittently as needed for disease control and highlights the importance of setting clear expectations for treatment use. She emphasizes proactive counseling around safety information and prescribing warnings to address patient concerns and support treatment adherence.
Topics Covered:
- Identifying appropriate patients with atopic dermatitis for topical ruxolitinib
- Clinical factors that influence topical treatment selection
- Setting expectations for early response and long-term disease management
